The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...